 RANCHO CUCAMONGA, Calif., March 29, 2021 GLOBE NEWSWIRE -- Amphastar Pharmaceuticals, Inc. NASDAQ: AMPH announced that the U.S. Food and Drug Administration FDA approved the Companys Abbreviated New Drug Application ANDA for Dextrose injection 50 in the 50 mL Luer-Jet Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the grandfather exception to the FDAs Prescription Drug Wrap-Up program. Net revenues for the Companys Dextrose injection for the year ended December 31, 2020, were 7.6 million. 